Asian Spectator


The Times

.

GrabSteel Enters into Committed Equity Facility of up to US$100 Million with White Lion Capital

Johor steel distributor, built to US$28 million without outside equity, arranges its first committed source of outside capital, available following a U.S. listing, to develop Matcon, a construction ma...

UL Granted Extended Volkswagen Approvals for Materials Testing

KREFELD, Germany, Oct. 9, 2019 /PRNewswire-AsiaNet/ -- UL, a leading global safety science company, officially announced two of its materials testing laboratories have been granted extended ...

SS C Unveils Advanced In-Region Data Storage for Japanese Clients

WINDSOR, Conn., June 3, 2021 /PRNewswire-AsiaNet/ -- -- SS&C Intralinks meets emerging demands for cross-border data securitySS&C Technologies Holdings, Inc. ( https://c212.net/c/lin...

Xi'an, China: Seeing the past and present across the millennia...

XI'AN, China, May 30, 2022 /Xinhua-AsiaNet/-- Throughout the millennia of history and the prosperous times of Chang'an, the profound cultural accumulation rooted in Xi'an, China, is a valuab...

LMRKTS Completes Successful Proof of Concept Simplifying ISDA...

NEW YORK and LONDON, March 3, 2021 /PRNewswire-AsiaNet/ -- LMRKTS, an industry-leading optimization and compression provider, announced today the successful completion of a proof of concept ...

Xinhua Silk Road: CEIS, Fitch Solutions jointly release report...

BEIJING, Oct. 17, 2019 /PRNewswire-AsiaNet/ -- China Economic Information Service (CEIS) of Xinhua News Agency and Fitch Solutions jointly released a report focusing on business opportunitie...

IN MOMS WE TRUST Global Virtual Summit

US, May 4, 2021 - (ACN Newswire) - You are cordially invited to join us for this Global Virtual Summit celebrating the voices of women & girls around the world as we discuss new paradig...

Japanese Government's Official E-magazine, "KIZUNA," Features ...

TOKYO, Feb. 8, 2023 /Kyodo JBN-AsiaNet/- "KIZUNA," the Government of Japan's official e-magazine, releases the latest issue: the budding drone industry in Fukushima Prefecture, Japanese effo...

NIPPON EXPRESS HOLDINGS Strengthens Pharmaceutical Logistics Q...

TOKYO, Mar. 9, 2023 /Kyodo JBN-AsiaNet/ -- - Compiles "NX-Pharma Global Quality Manual" and Appoints Head of NX-Pharma Global Quality -NIPPON EXPRESS HOLDINGS, INC., based in Tokyo, has comp...

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

SYDNEY, Apr 8, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech said the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations.

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

View and Download the COVID-19 Australia Data Bulletin here. https://novotech-cro.com/covid-19-notice

The data is part of a new series prepared for Novotech clients detailing the current status of trials in the Asia-Pacific during the global COVID-19 crisis.

Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.

"While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients," said Dr Moller. "Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia."

Australia has attractive start-up times, world leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.

About Novotech

Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotech companies.

Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media ContactSusan Fitzpatrick-Napiercommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

hacklink hack forum hacklink film izle hacklink StreamEastcashnow.imweb.mecasibomcasibomcasibomcasinos not on gamstopcasino sites not on gamstopnon gamstop sitescasinos not on gamstopnon gamstop casinoszlibraryzlibraryzlibraryjojobet girişturkbet girişjustin tvcasibomcasibomcasibomPorno siteleriPadişahbetjojobet